Waters (WAT) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" WAT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WAT, but not buy additional shares or sell existing shares.
View WAT analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month price objectives for Waters' stock. Their WAT share price forecasts range from $270.00 to $352.00. On average, they predict the company's share price to reach $312.78 in the next year. This suggests a possible upside of 14.1% from the stock's current price.
View analysts price targets for WAT or view top-rated stocks among Wall Street analysts.

Waters' stock was trading at $342.58 on January 1st, 2023. Since then, WAT shares have decreased by 20.0% and is now trading at $274.21.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our WAT earnings forecast.

Waters Co. (NYSE:WAT) posted its quarterly earnings results on Wednesday, August, 2nd. The medical instruments supplier reported $2.80 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.21. The medical instruments supplier had revenue of $740.58 million for the quarter, compared to analysts' expectations of $733.51 million. Waters had a net margin of 22.54% and a trailing twelve-month return on equity of 124.03%.
Read the conference call transcript.

ETFs with the largest weight of Waters (NYSE:WAT) stock in their portfolio include AXS Cannabis ETF (THCX), Invesco Water Resources ETF (PHO), VictoryShares THB Mid Cap ESG ETF (MDCP), Invesco Global Water ETF (PIO), Motley Fool Mid-Cap Growth ETF (TMFM), Nuveen ESG Mid-Cap Growth ETF (NUMG), Simplify Market Neutral Equity Long/Short ETF (EQLS) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH).

Waters updated its third quarter 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $2.50-$2.60 for the period, compared to the consensus EPS estimate of $3.01. The company issued revenue guidance of $721.46 million-$735.75 million, compared to the consensus revenue estimate of $769.19 million.

13 employees have rated Waters Chief Executive Officer Udit Batra on Glassdoor.com. Udit Batra has an approval rating of 100% among the company's employees. This puts Udit Batra in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), RTX (RTX), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Verizon Communications (VZ), Cisco Systems (CSCO) and Walmart (WMT).

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Shares of WAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WAT stock can currently be purchased for approximately $274.21.

Waters (NYSE:WAT) has a market capitalization of $16.21 billion and generates $2.97 billion in revenue each year. The medical instruments supplier earns $707.76 million in net income (profit) each year or $11.34 on an earnings per share basis.

The company employs 8,200 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The official website for the company is www.waters.com. The medical instruments supplier can be reached via phone at (508) 478-2000, via email at investor_relations@waters.com, or via fax at 508-872-1990.